Hanmi Pharm’s innovative anticancer drug ‘Posiotinib’ published in international SCI journal
A research result of Poziotinib, a targeted therapy for cancer developed by Hanmi Pharm, was registered in the online version of Nature Medicine, an international SCI(Science Citation Index) journal.
Spectrum Pharmaceuticals, a U.S. partner of Hanmi Pharm(CEO Sae-Chang Kwon & Jong-Soo Woo), anno...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
